NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

OCGN

OCGN US Stock
$5.45
Open: $5.73 High: $6.32 Low: $5.238 Close: $5.4
Range: 2021-04-19 - 2021-04-20
Volume: 26,092,734
Market: Extended-hours
Powered by Finage Stock APIDelayed data
OCGN
  • CEO:
  • Employees:
  • Sector:
  • Industry:
OCGN News
Latest news about the OCGN
  • Reddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks

    As shown by the GameStop mania earlier this year, Reddit traders are a market-moving force that shouldn't be underestimated. Recently, a couple of biotechs have sparked the imagination of the Reddit investing crowd. Ocugen (NASDAQ: OCGN) is a Reddit favorite in part because it will soon co-develop and manufacture a coronavirus vaccine that was originally developed by Bharat Biotech.

    View More →
  • 7 Reddit Penny Stocks to Buy for a Biotech Boom

    Penny stocks across all sectors have been popular with investors active on Reddit’s r/WallStreetBets subreddit. But, one area, in particular, they’ve found many of their favorites has been in the biotech space. Not only a lot of penny, or low-priced stocks, are in this industry. The high-risk, high-potential return nature of biotech investing makes it no surprise retail speculators online are active in this area. Earlier this year, Reddit investors sent many low-priced biotech names “to the moon.” But, in recent weeks, many of these popular names have pulled back from their highs. For some, this is justified. There was little going on to justify their inflated valuations. For others, though, there’s more in their corner than just online hype. For biotech names, things can be very make-or-break. News of Food and Drug Administration (FDA) approval can turn a stock parabolic. But, one hiccup, misstep, or stumble can send a biotech stock down 50%, 60%, even 75% in a day.InvestorPlace - Stock Market News, Stock Advice & Trading Tips In short, this isn’t an area you should bet the ranch on one opportunity. Yet, for those with an adequate risk appetite, and the discipline to size positions? You can find many opportunities where the potential for gains more than makes up for the high risk. 10 Stocks to Buy for Your $5K Robinhood Portfolio So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm: 180 Life Sciences (NASDAQ:ATNF) Citius Pharmaceuticals (NASDAQ:CTXR) Jaguar Health (NASDAQ:JAGX) Ocugen (NASDAQ:OCGN) Savara (NASDAQ:SVRA) Timber Pharmaceuticals (NYSEAMERICAN:TMBR) Zosano Pharma (NASDAQ:ZSAN) Penny Stocks: 180 Life Sciences (ATNF) Source: Iryna Imago / Shutterstock.com With its epic run over the past month, ATNF stock has rallied far above penny-stock status (less than $5 per share). But, with pulling back to single-digit prices, you may want to keep it on your radar. What’s been behind the dramatically increased interest in 180 Life Sciences? Increased awareness of the potential of its therapeutic candidates by Reddit investors helped to fuel its initial surge starting in March. But, recent news of insider buying helped this former penny stock rally above $10 per share. So, why could shares pull back? And, why may it be a great opportunity at lower prices? Namely, its possibility in bringing fibrosis and anti-TNF (anti-tumor necrosis factor) therapies to market. However, recent developments have been minimal. In turn, it’s hard to tell whether shares can continue to climb. Or, if there’s risk of a selloff just around the corner. Yet, if the company down the road makes progress with its pipeline, such news could give shares yet another boost. With Reddit investors onto something here, keep ATNF stock on your radar. Citius Pharmaceuticals (CTXR) Source: Shutterstock As has been par for the course with Reddit penny stocks, CTXR stock peaked during February’s madness. But, while news of a dilutive capital raise, along with fading enthusiasm for meme stocks, has resulted in shares pulling back nearly 39% off their highs, it may be premature to say it’s time to throw in the towel. What’s the “story” behind Citius? As InvestorPlace’s Louis Navellier broke it down March 22, the company has three promising candidates in its pipeline. These are blood infection treatment Mino-Lok, Mino-Wrap, a product to be used for preventing infections that can occur during breast reconstruction surgery, and Halo-Lido, an anti-inflammatory treatment for hemorrhoids. As discussed in its March 2021 investor presentation, Mino-Wrap and Halo-Lido have yet to move far down the pipeline. But, Mino-Lok is already in Phase 3 clinical trials. Further news signaling Mino-Lok’s eventual approval and commercialization will definitely be a needle-mover for CTXR stock. With a total addressable market of $1.5 billion, the financial rewards for this company could be massive. 10 Stocks to Buy for Your $5K Robinhood Portfolio While down from its February highs, shares at today’s prices (around $1.66 per share) are still up big from the start of 2020 (when it traded for around $1 per share). Yet, given the possible game-changers in its pipeline, consider it well worth the risk. Jaguar Health (JAGX) Source: Spyro the Dragon/Shutterstock.com What’s the story with JAGX stock, once one of the most popular penny stocks among Reddit investors? It’s a biotech name with a novel coronavirus catalyst. No, it doesn’t have a vaccine in its pipeline. As I discussed back in February, the company is one of many names focused on chronic Covid treatment. How? Via its Mytesi treatment. Mytesi was first created for HIV/AIDS patients with antiretroviral therapy-related chronic diarrhea. But, it may have potential as a treatment for those suffering from long-term Covid-19 symptoms. Before, Reddit investors got carried away with JAGX stock. Its valuation rose to levels way beyond the possible Covid-related upside. But, now, the stock has fallen by more than 50%. That’s not to say the stock is cheap, by any means. But, following its selloff, any positive news on Mytesi may be enough to fuel a rebound. Jaguar Health has other promising candidates in its pipeline, including its Canalevia chemotherapy-induced diarrhea treatment for dogs. Yet, so much riding on Mytesti, exercise some caution. Any positive news could send it surging again. But, negative developments could send it back to prices well below $1 per share. Penny Stocks: Ocugen (OCGN) Source: Shutterstock Like with ATMF stock, OCGN stock is a former penny stock that’s moved beyond $5 per share. Hype with this Covid-19 vaccine play may be off-the-charts. But, even with its vaccine contender a long shot, that doesn’t mean shares could again make another rip higher. How so? While it’s a bit late to the party, with Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) now widely distributing their vaccines, Ocugen may find success, as it tries to bring India-based Bharat Biotech’s Covaxin candidate to the United States. With U.S. Government pausing distribution of Johnson & Johnson’s (NYSE:JNJ) vaccine, there may be opportunity for some of the also-rans to get emergency use authorization (EUA). Initial news of the Covaxin deal sent it from around $1 per share to more than $19 per share. But, the stock has since sold off. So far, the JNJ vaccine news hasn’t done much to renew confidence in Ocugen’s prospects. 10 Stocks to Buy for Your $5K Robinhood Portfolio Yet, with this recent news possibly paving the way for this long-shot Covid-19 vaccine contender to get U.S. regulatory approval, it may be worth it to take a calculated bet on OCGN at today’s prices. Savara (SVRA) Source: Shutterstock Since moving from around $1.20 per share to around $1.80 per share, Savara stock has traded sideways. But, this developer of respiratory therapies may have a shot of breaking out to substantially higher price levels. At least, that’s the view of Oppenheimer’s Francois Brisebois, who last month initiated coverage on the stock. Giving SVRA stock the equivalent of a “buy” rating, and a price target of $4 per share, the analyst is bullish on the prospects of the company’s Molgradex candidate. This candidate is a treatment for aPAP, or autoimmune pulmonary alveolar proteinosis. So, why haven’t investors been more excited about this stock? The on-the-fence view of Savara may have to do with its recent $130 million secondary offering. This transaction raised much-needed capital to sustain its operations. But, it’s come at the cost of heavy shareholder dilution. This dilution could limit to what extent SVRA stock gains if Molgradex becomes a marketable product. Even so, with the high confidence this flagship candidate will live up to expectations, buying this stock, as investors remain on the fence, could be a profitable move in hindsight. Timber Pharmaceuticals (TMBR) Source: Shutterstock Timber Pharmaceuticals is yet another of the Reddit penny stocks that’s been a roller-coaster ride so far this year. Shares in this developer of treatments for rare dermatologic diseases started the year off trading for around 80 cents per share. But, at the height of meme stock/Reddit stock madness, shares briefly hit prices above $3 per share. But, except for another brief spike above $3 per share in March, shares have since fallen back to around $1.50 per share. As much of its Reddit hype has begun to fade, focus now returns to the underlying fundamentals of TMBR stock. So, does Timber have potential to become a long-term winner? Or, will shares pull back to prior levels? Admittedly, it’s too hard to tell right now. With most of its pipeline still in Phase 2 trials, it may take some time to determine whether it has a marketable product in its hands. 10 Stocks to Buy for Your $5K Robinhood Portfolio But, biotech penny stocks remain popular with retail traders. This may be enough to keep TMBR stock steady. News related to its BPX-01 and BPX-04 candidates, currently in late stage clinical trials, could help fuel another rally back to $3 per share and above. Approach it cautiously, but this remains a Reddit biotech play to keep an eye on. Penny Stocks: Zosano Pharma (ZSAN) Source: Shutterstock Zosano Pharma, which is developing a transdermal microneedle treatment for migraines called Qtrypta, grabbed the attention of Reddit traders earlier this year. Like many other biotech names, shares saw a dramatic uptick in February, followed by an extended cooling off period. Today, ZSAN stock is down more than 65% off its highs. But, given shares were trading for around 60 cents per share at the end of 2020, at today’s prices ($1 per share) it’s still up substantially. That may leave some worried shares have more room to fall, as enthusiasm continues to cool. But, to some extent, the story’s improved with Zosano. The company has made some progress obtaining approval for Qtrypta. Last fall, the FDA rejected Zozano’s initial application for Qtrypta. But, it’s not giving up on its flagship candidate. With plans for a new study, the company has high hopes the second go-around with the FDA will be a success. Yet, this slight improvement in its prospects may already be factored into the stock price. More positive news will likely produce another outsized rally for ZSAN stock. It’s still a gamble, but it may be one that pays off in the end. On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post 7 Reddit Penny Stocks to Buy for a Biotech Boom appeared first on InvestorPlace.

    View More →
  • 3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?

    You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now. The biggest factor driving investors' interest in Aphria is the company's plans to merge with Tilray (NASDAQ: TLRY).

    View More →
  • Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain

    John Paul (J.P.) Gabriel John Paul (J.P.) Gabriel MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that John Paul (J.P.) Gabriel will be joining as Senior Vice President (SVP), Manufacturing and Supply Chain. John Paul (J.P.) Gabriel is a seasoned biopharmaceutical manufacturing professional with over 25 years of industry experience. Over the course of his career, Mr. Gabriel has held leadership positions with Sanofi Pasteur (formerly Connaught Laboratories), Pfizer Vaccines (formerly Wyeth), Genentech/Roche, and most recently with Ultragenyx Pharmaceutical, where he was Vice President of Biologics and mRNA Manufacturing. “We are pleased to welcome J.P. to the Ocugen team as we continue to plan for COVAXIN manufacturing in the US. As an established biopharma and vaccines operations leader, J.P. brings a wealth of manufacturing experience that will be instrumental in the technology transfer from Bharat Biotech for manufacturing in the U.S. market,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. “I’m thrilled to be part of the Ocugen team and share the team’s dedication to save lives from COVID-19. Bringing COVAXIN to the US market will be an important addition to our national arsenal of vaccines against COVID-19,” said J.P. Gabriel, SVP, Manufacturing and Supply Chain of Ocugen. In addition to his expertise in biomanufacturing, Mr. Gabriel led teams in quality and validation and has extensive experience interacting with various international health authorities. He has broad international business knowledge gained from work assignments in Canada, Switzerland, Japan, Mexico, and the United States. Mr. Gabriel earned an Honors Bachelor of Science in Biological Sciences with a Major in Microbiology and Minor in Biotechnology from the University of Guelph in Canada and an Advanced Certificate in Regulatory Affairs from the University of California San Diego. About Ocugen, Inc.Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Ocugen Contact:Ocugen, Inc.Sanjay SubramanianCFO and Head of Corp. Dev. IR@Ocugen.com Media Contact: LaVoieHealthScience Lisa DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6048f2f-29a9-4b24-8526-07d6e5371303

    View More →
  • 5 Stocks That Made People Millionaires in 6 Months

    With gains of 1,259% to 2,801%, these billion-dollar stocks have been unstoppable since early October.

    View More →
  • Ocugen's Charts Suggest We Look for a Better Buying Opportunity

    Here's what Jim Cramer had to say about some of the stocks that callers offered up during the Mad Money "Lightning Round" Tuesday evening - Ocugen : "This is a good speculative stock," Cramer told the caller. The company used to be called Histogenics Corp. and is a clinical stage biopharmaceutical firm that is focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. In this daily Japanese candlestick chart of OCGN, below, we find some interesting clues.

    View More →
  • Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?

    Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

    View More →
  • Should You Buy Ocugen in April?

    It's easier for small, new companies to keep growing after such a massive expansion, and that's exactly why Ocugen (NASDAQ: OCGN) is still in play for future skyrocketing. Ocugen is a very young biotech company that's already made a name for itself by being confident enough to dabble in diverse fields like gene therapy and coronavirus vaccines, and its roller coaster of a stock could still have more peaks and valleys ahead. In February, the company struck a deal with Bharat Biotech to manufacture the Covaxin coronavirus vaccine, which was recently shown to be safe and 81% effective in a phase 3 clinical trial in India.

    View More →
  • Ocugen (OCGN) Stock Sinks As Market Gains: What You Should Know

    Ocugen (OCGN) closed the most recent trading day at $6.70, moving -1.33% from the previous trading session.

    View More →
  • Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development

    MALVERN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at a virtual Fireside Chat hosted by Cantor Fitzgerald and Kristen Kluska, Biotechnology Analyst, on March 31, 2021 from 10:00 a.m. - 11:00 a.m. ET. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will participate along with members of the Ocugen Vaccine Scientific Advisory Board to discuss COVAXIN COVID-19 vaccine development. Topics will include: Discussion on all COVAXIN safety and efficacy data generated to date from Bharat Biotech (private), including Phase 1, Phase 2, and interim Phase 3 data which demonstrated 81% efficacy.Differentiation of COVAXIN (whole-virion inactivated vaccine) vs. other COVID-19 mRNA and adeno-based vaccines, including potential for coverage against multiple protein antigens of the virus.Thoughts on the current pandemic situation including new variants emerging.Highlight where the company views the greatest opportunity for COVAXIN in the United States, where they will receive 45% of the profits from any product sales. Ocugen’s Vaccine Scientific Advisory Board members participating include: Satish Chandran, PhD – Wyeth Vaccines, Pfizer, Nucleonics, Somahlution; David Fajgenbaum, MD, MBA, MSc, FCPP – Translational Medicine & Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment & Laboratory; and Bruce Forrest, MB, BS, MD, MBA – Wyeth Vaccines, Pfizer. Presentation Details: Format: Virtual Fireside ChatDate: March 31, 2021Time: 10:00 a.m. ET- 11:00 a.m. ETRegistration Link: https://us02web.zoom.us/webinar/register/WN_DKZBH0wuRo-5udQpml48qg About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data that is referenced in this release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Ocugen Contact:Ocugen, Inc.Sanjay SubramanianChief Financial Officer and Head of Corporate DevelopmentIR@Ocugen.com Media Contact: LaVoieHealthScience Lisa DeScenzaldescenza@lavoiehealthscience.com+1 9783955970

    View More →
  • Is Approval Even Enough for Ocugen Stock?

    Last year, I wrote that the most likely outcome for Ocugen (NASDAQ:OCGN) stock was that it would hit zero. Seven months later, OCGN stock is above $7 and Ocugen has a market capitalization well past $1 billion. Source: Shutterstock.com Of course, this is a very different Ocugen than it was last August. Given what we knew at the time, particularly concerning Ocugen’s balance sheet, the risk of bankruptcy was significant. The company’s OCU300 candidate for oGVHD (ocular graft versus host disease) had failed. Ocugen itself saw no potential for commercialization elsewhere in the pipeline until 2025 at the earliest. But in December, Ocugen announced it had partnered with India’s Bharat Biotech to bring Bharat’s Covid-19 vaccine candidate Covaxin to the U.S. market. OCGN stock rose 800% in two days on the news. An equity offering unusually priced at a premium to the market price in February further ignited the rally.InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’ve seen a 50%-plus pullback from the highs, which might in context seem like an opportunity. Bharat has continued to provide positive, if early, data on Covaxin. Ocugen’s balance sheet is improved, and the higher share price alone gives the company the option of raising additional capital. 7 Risky Stocks Ready to Roll on Reopening But even cut in half, and even assuming Covaxin approval, OCGN stock has very real valuation concerns at the moment. We’re perhaps getting closer to where the stock might get interesting, but at the moment this still doesn’t seem like quite the bargain so many bulls believe it to be. Understanding Valuation Ocugen now has 188 million shares outstanding. Its market capitalization sits right at $1.4 billion. At this point, essentially all of that value has to come from Covaxin. Again, OCGN soared on the initial announcement of the Bharat partnership. Part of why it soared was because of optimism toward the deal. But another cause was the fact that Ocugen wasn’t worth very much before the deal was announced. In fact, the day before the announcement, OCGN stock closed at 29 cents. At the time, Ocugen had about 162 million shares outstanding (the equity offering this year, along with ‘at the market’ sales, have since expanded the share count). So, this was a business that, before Bharat, was valued at about $47 million. And at the moment, that’s probably still our best guess of the value of the ophthalmology franchise. This isn’t a story like Moderna (NASDAQ:MRNA), where success on the Covid-19 front creates additional optimism toward the rest of the pipeline. Ocugen wasn’t even involved in developing Covaxin. Certainly, the fact that Ocugen has raised some capital, and could raise more by selling additional stock, helps the cause for the legacy business. But even if that access to capital doubles the valuation, it still doesn’t really move the needle against the $1.4 billion market capitalization. A 45% Profit Split An investor bullish on OCGN stock has to believe, roughly speaking, that Ocugen can garner something like $2 billion in profit from the Bharat vaccine. That’s enough to account for the time value of money as well as some upside from the current stock price, while also assuming, for now, that Covaxin indeed receives U.S. approval. Here’s the thing: $2 billion is a big number. Yes, there’s a big opportunity. Yes, it increasingly looks like Covid-19 vaccines will require repeated doses. But the products from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), Moderna, and Johnson & Johnson (NYSE:JNJ) already are on the market. Novavax (NASDAQ:NVAX) might be on the way. Any number of smaller players retain their own hopes. Meanwhile, Ocugen only gets a 45% share of the profits. It’s only commercializing Covaxin in the U.S. market. So, the $2 billion figure for Ocugen now moves closer to $4.5 billion total profits for Covaxin. That’s over $13 for every man, woman, and child in the U.S. Suddenly, a lot of success still looks priced in. Is OCGN Stock Cheap? The profit split and the market limitation both hurt OCGN in terms of relative valuation. It’s easy to look at Novavax ($14 billion market cap) or Moderna ($53 billion) and see the $1.4 billion valuation as Ocugen as cheap. But cut profits by more than half, and limit the market to 5% of the world’s population. Suddenly, those relative valuations make a lot more sense. Then add in Moderna’s approval and Novavax’s more valuable and reliable existing pipeline and OCGN stock no longer looks like a bargain. The discussion so far doesn’t even contemplate the two biggest risks. First, Covaxin might not get U.S. approval. Bharat still has only preliminary data. Even the approval in India garnered its share of controversy. In that event, OCGN stock realistically could drop by 90%. Second, Ocugen still has to build out its infrastructure. It’s responsible for Covaxin in the U.S. That might take more cash. At Feb. 28, the company had $46.6 million in cash. It burned $15 million in 2020. In theory, that burn rate suggests Ocugen is safe until 2023. Lower spending on the legacy business, with the discontinuation of OCU300, may offset some of the expense related to Covaxin. Still, another equity offering, possibly toward the end of this year, is not off the table. I’m skeptical Ocugen can again do such an offering above the market price. (To be fair, those investors did pay a touch above the current price.) None of this is to say that Covaxin won’t be approved, or that Ocugen won’t be able to market it. That’s not the problem. The problem is the risk/reward. There are still a number of risks. And even after the pullback, the rewards don’t yet look all that great. On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Is Approval Even Enough for Ocugen Stock? appeared first on InvestorPlace.

    View More →
  • Why Is Everyone Talking About Ocugen Stock?

    On Dec. 1, 2020, Ocugen (NASDAQ: OCGN) had a market cap of just over $55 million. On Dec. 22, 2020, Ocugen announced that it would be working with Indian-based Bharat Biotech to develop Covaxin, a COVID-19 vaccine candidate, for the U.S. market. It was perfect timing because the news came not long after vaccines from Pfizer and Moderna received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

    View More →
  • 3 Top Value Stocks to Buy Now

    Here's why a coronavirus vaccine developer, a groundbreaking financial service company, and a 3-D printing manufacturer can make investors wealthy.

    View More →
  • Ocugen: Potential Covid-19 Vaccine EUA Warrants a Buy, Says Analyst

    Ocugen (OCGN) has been one of 2021’s biggest and unlikeliest success stories. The eye disease specialist has shifted its focus to getting another Covid-19 vaccine to market. For investors, it is a move that has paid off, so far; the stock is up by a massive 366% year-to-date. The company reported 4Q20 earnings last week, and H.C. Wainwright analyst Swayampakula Ramakanth believes the company’s cash position of $47 million should be enough to support its operations into 2023. Going by Ramakanth’s revenue estimates for 2021, the company’s position should improve substantially by then. In 2021, the analyst projects revenues of $280 million and diluted EPS of $1.10. Ramakanth’s forecasts assume the company gains regulatory approval for COVAXIN, the Covid-19 vaccine India-based Bharat Biotech is developing. Ocugen has inked a deal with Bharat to bring COVAXIN to the US, where the company will oversee clinical development, getting the vaccine approved by the regulators and take on all U.S. commercialization aspects. In return, Ocugen will get to keep 45% of any profits. COVAXIN has already been granted emergency use authorization in India, even before interim analysis of its Phase 3 trial showed an efficacy rate of 81%. “Albeit preliminary,” says Ramakanth, “The 81% efficacy places COVAXIN ahead of adenovirus vaccines, and behind only two approved mRNA vaccines in terms of efficacy, which we believe bodes well for its potential U.S. regulatory approval and market opportunity.” Once Bharat holds the data of 87 cases (the initial interim readout was based on 43 cases), the company expects to perform an additional interim analysis and after 130 cases, will conduct the final analysis. Once the safety data of 60 days following the second dose becomes available, Ocugen plans to meet with the FDA and discuss COVAXIN’s regulatory pathway, which Ramakanth thinks should be sometime in April. “We believe a green light from the regulator that allows applying for EUA [Emergency Use Authorization] could be the next catalyst for OCGN,” the 5-star analyst summed up. To this end, Ramakanth reiterated a Buy rating on OCGN shares, backed by a $12 price target. The implication for investors? Possible upside of 40%. (To watch Ramakanth’s track record, click here) Ramakanth’s objective sits just below the Street’s $12.50 average price target, which suggests gains of 46% in the year ahead. Based on a total of 3 Buys vs. 1 Hold, the analyst consensus rates this stock a Strong Buy. (See OCGN stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

    Biotech investors are probably a little depressed, with valuations of the industry down since their peak in February. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights explain why smaller development-stage companies have been hit especially hard during the downturn.

    View More →
  • Ocugen, Inc. (OCGN) Q4 2020 Earnings Call Transcript

    With me today are Ocugen's chairman and CEO, Dr. Shankar Musunuri; and our CFO and head of corporate development, Sanjay Subramanian. Earlier this morning, Ocugen issued a press release, including a business update and full-year 2020 financial results.

    View More →
  • Top Biotech Stocks for Q2 2021

    The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

    View More →
  • What Really Mattered With Ocugen's Q4 Update

    Few stocks have delivered jaw-dropping gains the way Ocugen (NASDAQ: OCGN) has so far in 2021. Ocugen announced its fourth-quarter results before the market opened on Thursday. Ocugen reported collaboration revenue of $42,620.

    View More →
  • Ocugen Provides Business Update and Full Year 2020 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim resultsEmergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™European Commission grants orphan medicinal product designation for OCU400 for retinitis pigmentosa and leber congenital amaurosis and Ocugen is on track to submit an Investigational New Drug application for OCU400 in 2021On track to initiate four Phase 1/2 clinical trials encompassing Ocugen’s ophthalmology pipeline in 2021 and 2022 MALVERN, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported full year 2020 financial results along with a general business update. “We made strong progress toward our goal of offering a differentiated vaccine to save lives from COVID-19 and in our work toward curing blindness diseases. We are actively working with U.S. regulatory authorities to develop a plan around Emergency Use Authorization in the United States for COVAXIN™ and are preparing to file an Investigational New Drug application to initiate our first two clinical trials for OCU400 in the second half of this year. Proceeds from our recent registered direct offering provide the financial resources to drive our COVAXIN™ development efforts and ophthalmology pipeline forward,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. Business Highlights: Execution of Co-Development Agreement for COVAXIN™ in the U.S. Market – On February 2, 2021, Ocugen entered into a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited (“Bharat Biotech”) for the development and commercialization of COVAXIN™ in the U.S. market. Upon receipt of Emergency Use Authorization (“EUA”), Bharat Biotech will supply a specified minimum number of doses of COVAXIN™ and then support the technology transfer for manufacturing for the U.S. market. Ocugen will share the profits from the sale of COVAXIN™ in the U.S. market with Bharat Biotech, with Ocugen retaining 45% of the profits.Steady Progress to Develop EUA Pathway in the United States for COVAXIN™ Supported by U.S. Leading Experts in Vaccines – Key members of Ocugen’s management team and key advisors possess proven expertise and a track record of success in vaccine development and commercialization. Ocugen has established a vaccine scientific advisory board composed of leading academic and industry experts with extensive experience in the vaccine field. Collectively, the team is working with U.S. regulatory authorities to develop the regulatory pathway to EUA in the U.S. market.COVAXIN™ Demonstrates Efficacy of 81% in Phase 3 Interim Results – Interim results from Bharat Biotech’s Phase 3 trial in India showed that COVAXIN™ was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose. In addition, COVAXIN™ has been shown to induce immune responses against multiple protein antigens of the virus potentially reducing the possibility of mutant virus escape. This breadth of immune responses has been demonstrated by the ability of antibodies induced by COVAXIN™ to neutralize the U.K. variant of SARS-CoV-2. This broad-antigen containing vaccine has the potential to be effective against new emerging variants.First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2H21 – Based on Ocugen’s modifier gene therapy platform, Ocugen’s product candidate OCU400 represents a novel approach in that it has the potential to address multiple retinal diseases with one product. Ocugen is planning to file an Investigational New Drug application to initiate two Phase 1/2 clinical trials of OCU400 later this year for the treatment of two disease genotypes.European Commission (“EC”) Grants Orphan Medicinal Product Designation for OCU400 for Retinitis Pigmentosa (“RP”) and Leber Congenital Amaurosis (“LCA”) – Designation by the EC further supports the potential broad spectrum application of OCU400 to treat many IRDs. IRDs associated with RP and LCA diseases are caused by mutations in over 175 genes, and it is impractical to develop therapies that are specific to each gene.Capital Raised – Ocugen’s cash, cash equivalents, and restricted cash totaled approximately $46.6 million as of February 28, 2021. Subsequent to December 31, 2020, Ocugen generated net proceeds of $4.8 million under an at-the-market offering and net proceeds of $21.2 million under a registered direct offering. Full Year 2020 Financial Results: Ocugen’s cash, cash equivalents, and restricted cash totaled $24.2 million as of December 31, 2020, compared to $7.6 million as of December 31, 2019. The Company had 184.0 million shares of common stock outstanding as of December 31, 2020.Research and development expenses for the year ended December 31, 2020 were $6.4 million compared to $8.1 million for the year ended December 31, 2019. General and administrative expenses for the year ended December 31, 2020 were $8.0 million compared to $6.1 million for the year ended December 31, 2019. Ocugen reported a $0.31 net loss per share for the year ended December 31, 2020 compared to a $1.46 net loss per share for the year ended December 31, 2019. Conference Call and Webcast Details Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks. The call can be accessed by dialing (844) 873-7330 (U.S.) or (602) 563-8473 (international) and providing the conference ID 2375087. To access a live audio webcast of the call on the “Investors” section of the Ocugen website, please click here. A replay of the webcast will be archived on Ocugen’s website for approximately 45 days following the call. About Ocugen, Inc.Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data related to COVAXIN™), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (“FDA”) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or EUA applications may be filed in the United States for COVAXIN™; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. This press release contains a preliminary estimate of Ocugen’s cash, cash equivalents, and restricted cash as of February 28, 2021. The preliminary estimate should not be viewed as a substitute for interim financial statements prepared in accordance with U.S. generally accepted accounting principles. The preliminary estimate is based on preliminary unaudited information and management estimates as of February 28, 2021, is not a comprehensive statement of Ocugen’s financial results, and is subject to the completion of Ocugen’s financial closing procedures. As a result, this preliminary estimate may differ from the actual results that will be reflected in Ocugen’s financial statements when they are completed and publicly disclosed. Additional information and disclosures would be required for a more complete understanding of Ocugen’s financial position as of February 28, 2021. Ocugen’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the preliminary estimate. Corporate Contact:Ocugen, Inc.Sanjay SubramanianChief Financial Officer and Head of Corporate DevelopmentIR@Ocugen.com Media Contact:LaVoieHealthScienceLisa DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970 (tables to follow)OCUGEN, INC.CONSOLIDATED BALANCE SHEETS(UNAUDITED) December 31,2020 December 31,2019Assets Current assets Cash and cash equivalents$24,039,325 $7,444,052 Prepaid expenses and other current assets1,838,357 1,322,167 Asset held for sale— 7,000,000 Total current assets25,877,682 15,766,219 Property and equipment, net632,967 222,464 Restricted cash151,226 151,016 Other assets714,477 667,747 Total assets$27,376,352 $16,807,446 Liabilities and stockholders’ equity Current liabilities Accounts payable$395,034 $1,895,613 Accrued expenses2,930,395 2,270,045 Short-term debt, net234,119 — Operating lease obligation44,248 172,310 Other current liabilities9,755 205,991 Total current liabilities3,613,551 4,543,959 Non-current liabilities Operating lease obligation, less current portion389,317 163,198 Long term debt, net1,823,043 1,072,123 Other non-current liabilities— 9,755 Total liabilities5,825,911 5,789,035 Stockholders’ equity Common stock1,841,334 527,467 Treasury Stock(47,864) (47,864)Additional paid-in capital93,058,748 62,018,632 Accumulated deficit(73,301,777) (51,479,824)Total stockholders’ equity21,550,441 11,018,411 Total liabilities and stockholders’ equity$27,376,352 $16,807,446 OCUGEN, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) Year ended December 31, 2020 2019Revenues Collaboration revenue$42,620 $— Total revenues42,620 — Operating expenses Research and development6,353,287 8,085,522 In-process research and development7,000,000 — General and administrative7,974,050 6,077,097 Total operating expenses21,327,337 14,162,619 Loss from operations(21,284,717) (14,162,619)Other income (expense) Change in fair value of derivative liabilities— (3,187,380)Loss on debt conversion— (341,136)Interest income1,065 1,214 Interest expense(720,963) (1,767,836)Other income (expense)182,662 (784,873)Total other income (expense)(537,236) (6,080,011)Net loss$(21,821,953) $(20,242,630)Deemed dividend related to Warrant Exchange(12,546,340) — Net loss to common stockholders$(34,368,293) $(20,242,630) Shares used in calculating net loss per common share — basic and diluted112,236,110 13,893,819 Net loss per share of common stock — basic and diluted$(0.31) $(1.46)

    View More →
  • Ocugen Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Ocugen Inc (NASDAQ:OCGN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

    View More →